Comparing Opus Genetics (IRD) & Its Peers

Opus Genetics (NASDAQ:IRD) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Opus Genetics to similar businesses based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, valuation and earnings.

Volatility and Risk

Opus Genetics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Opus Genetics’ competitors have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Profitability

This table compares Opus Genetics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	N/A	-150.13%
Opus Genetics Competitors	-12,357.18%	-197.96%	-30.56%

Institutional & Insider Ownership

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Opus Genetics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	16	1	2.89
Opus Genetics Competitors	9838	15122	45436	1587	2.54

Opus Genetics currently has a consensus price target of $12.71, indicating a potential upside of 204.17%. As a group, “Biotechnology” companies have a potential upside of 102.59%. Given Opus Genetics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Opus Genetics is more favorable than its competitors.

Valuation & Earnings

This table compares Opus Genetics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Opus Genetics	$9.86 million	-$49.59 million	-3.10
Opus Genetics Competitors	$728.25 million	$12.25 million	-15.19

Opus Genetics’ competitors have higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Opus Genetics beats its competitors on 7 of the 13 factors compared.

Opus Genetics Company Profile

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.